Using a pilot system we have categorised this review as: Historical question - no update intended. Please see "Published notes" section of the review for more details.
Since 2001, the World Health Organization has recommended that antimalarial drug combinations be used for uncomplicated falciparum malaria and that monotherapy should no longer be used.
阅读完整摘要
Using a pilot system we have categorised this review as: Historical question - no update intended. Please see "Published notes" section of the review for more details.
Since 2001, the World Health Organization has recommended that antimalarial drug combinations be used for uncomplicated falciparum malaria and that monotherapy should no longer be used. For the most up-to-date information on malaria combination treatment, please refer to Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD007483. DOI: 10.1002/14651858.CD007483.pub2.
Amodiaquine has been widely used to treat malaria. Fatal adverse reactions have been reported in adults taking it for prophylaxis. This has led some authorities to suggest it is withdrawn as a first line treatment for malaria.
研究目的
To compare amodiaquine with chloroquine or sulfadoxine-pyrimethamine for treating uncomplicated Plasmodium falciparum malaria.
检索策略
We searched the Cochrane Infectious Diseases Group specialized trials register (February 2003), The Cochrane Central Register of Controlled Trials (The Cochrane Library Issue 1, 2003), MEDLINE (1966 to February 2003), EMBASE (1980 to December 2002), LILACS (February 2003). We contacted researchers in the field and pharmaceutical companies.
纳入排除标准
Randomised and quasi-randomised trials.
资料收集与分析
Two reviewers independently extracted data and assessed trial quality.
主要结果
56 studies included, mostly from Africa. Treatment allocation was adequately concealed in three trials, and unclear or inadequate in the remainder. Amodiaquine was more effective than chloroquine for parasite clearance (day 7, Peto odds ratio 4.42 (95% confidence interval 3.65 to 5.35); day 14, Peto odds ratio 6.44 (95% confidence interval (CI) 5.09 to 8.15). Comparisons with sulfadoxine/pyrimethamine were more mixed, with sulfadoxine/pyrimethamine more effective on day 28 (Peto odds ratio 0.41; 95% CI 0.28 to 0.61). No significant difference for adverse events was observed between amodiaquine and chloroquine and sulfadoxine/pyrimethamine. Reported adverse effects were minor or moderate. No life threatening events were detected.
作者结论
There is evidence to support the continued use of amodiaquine to treat uncomplicated malaria, although local drug resistance patterns need to be considered. Monitoring for adverse events should continue.
This review summarizes trials up to 2003. For the reasons in the 'What's new' section, this review will no longer be updated.
